CSIMarket


Us-china Biomedical Technology, Inc.  (CLDS)
Other Ticker:  
 
    Sector  Services    Industry Advertising
   Industry Advertising
   Sector  Services


 

Us-china Biomedical Technology, Inc.

CLDS's Financial Statements and Analysis



Us-china Biomedical Technology, Inc. narrowed first quarter of 2020 net loss per share of $-0.01 compare to net loss per share of $-0.02 recorded in the same quarter a year ago a decrease compare to $-0.01 realized in previous quarter.


first quarter of 2020
Earnings Per Share Revenues
$ -0.01 $  0 Mill
$+0.01     Unch.    



Us-china Biomedical Technology's Revenue fell by 0 % in first quarter of 2020 (May 31 2019) year on year, to $0 million and declined by sequentially.


Us-china Biomedical Technology is

More on CLDS's Income Statement



Us-china Biomedical Technology's in thefirst quarter of 2020 recorded net loss of $-0.123 million, an improvement compare to net loss of $-0.275 million in I. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-0.174 million realized in previous quarter.

More on CLDS's Growth

Us-china Biomedical Technology Inventories
CLDS's Cash flow In the first quarter of 2020 company's net cash flow was $0 million


Us-china Biomedical Technology, Inc. does not pay out common stock dividend.

In trailing twelve-month period Us-china Biomedical Technology, Inc. payed $ -0.03 cash per share, on a free-cash flow basis .

Book value grew by 5,102.28 % sequentially to $0.00 per share.
Tangible Book value grew to $ 0.00 per share from $ 0.00.

Company issued 4.21 million shares or 27.16 % in May 31 2019.


More on CLDS's Dividends

 Market Capitalization (Millions) 759
 Shares Outstanding (Millions) 20
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -1
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 2




Us-china Biomedical Technology, Inc. does not pay out common stock dividend.

In trailing twelve-month period Us-china Biomedical Technology, Inc. had negative $ -0.03 cash flow per share, on a free-cash flow basis .

Book value grew by 5,102.28 % sequentially to $0.00 per share.
Tangible Book value grew to $ 0.00 per share from $ 0.00.

Company issued 4.21 million shares or 27.16 % in May 31 2019.


More on CLDS's Balance Sheets

 Market Capitalization (Millions) 759
 Shares Outstanding (Millions) 20
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -1
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 2
   



Date modified: -0001-11-30T00:00:00+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com